CareDx (CDNA) Announces $50 Million Stock Repurchase Program

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its Board of Directors has authorized a common stock repurchase program of up to $50 million of shares over a period of up to 24 months.

Under the repurchase program, CareDx may purchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions or other means, including through Rule 10b5-1 trading plans or through the use of other techniques. The timing and number of shares repurchased, and the price of any repurchases, will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The repurchase program does not obligate CareDx to acquire a specified number of shares and may be modified, suspended, or discontinued at any time at CareDx’s discretion.

Repurchases under this program will be funded from CareDx’s existing cash and cash equivalents or future cash flow.

“The opportunity to do share buybacks reflects our confidence in the business, cash position, long-term growth opportunities, and our conviction in the durable value of our shares,” said Reg Seeto, CEO and President of CareDx. “We remain 100 percent focused on driving the next wave of transplant innovation and will continue to invest in research and strategic acquisitions that advance our goals and deliver long-term shareholder value.”

You May Also Be Interested In

• flyExclusive says Jet.AI merger needs 22,500 more votes to pass
• Kadima sues NRx Pharmaceuticals over failed acquisition deal
• NovaRed Mining adds Katie Zacharia to its advisory board